Moderna +177%, Merck +13% on Melanoma Vaccine Phase 3 Win

Moderna (NASDAQ: MRNA) had one of the largest single-day rallies in large-cap biotech history on Tuesday, closing up 176.97% at $174.38 after the company and partner Merck (NYSE: MRK) reported that their personalized cancer vaccine intismeran autogene hit the primary endpoint of the Phase 3 INTerpath-001 trial in high-risk resected melanoma when combined with Merck’s blockbuster checkpoint inhibitor Keytruda. Merck itself closed up 12.60% at $152.20, a record high for the drugmaker, according to Yahoo Finance.

The move added roughly $45 billion to Moderna’s market capitalization in a single session, taking the company back near the valuation range it commanded during the peak of its COVID-19 vaccine cycle. In after-hours trading, MRNA changed hands at $183.01, indicating institutional demand was not exhausted at the close.

The snapshot: what actually moved

What the trial showed

INTerpath-001 is the confirmatory Phase 3 study of intismeran autogene — a patient-specific mRNA cancer vaccine that encodes up to 34 neoantigens unique to the patient’s own tumor — added to standard-of-care Keytruda in adults with resected Stage IIB to IV melanoma at high risk of recurrence. The primary endpoint is recurrence-free survival (RFS), meaning how long patients live without their cancer coming back after surgery. Merck and Moderna announced that the combination met that endpoint with a “statistically significant and clinically meaningful” improvement over Keytruda alone, and that the safety profile was consistent with the earlier randomized Phase 2b (KEYNOTE-942) readout.

Detailed hazard ratios, subgroup data, and distant metastasis-free survival results are being reserved for a medical meeting, per the companies’ joint statement. Both firms said they intend to engage regulators immediately, with a global filing strategy anchored to the FDA. The FDA had already granted intismeran Breakthrough Therapy Designation and PRIME status from the EMA on the strength of the Phase 2b data, so the regulatory path is well-worn.

Why the move was this large

Three factors compounded to produce a nearly 3x move in a $23 billion company:

• The setup was priced for failure. MRNA had traded near multi-year lows before the readout as investors wrote off the mRNA platform outside of COVID. The stock’s 3-month implied volatility was elevated but skewed bearish going into the event.
• The endpoint was hard. RFS in resected melanoma is the same endpoint that got Keytruda itself approved in the adjuvant setting; hitting it with a statistical win means the combination could plausibly become new standard of care rather than a niche add-on.
• The addressable market is large. Adjuvant melanoma alone represents tens of thousands of U.S. patients per year, and success here re-rates the entire personalized neoantigen platform for lung, kidney, and head-and-neck indications that are already in clinical development.

Move context: MRNA vs MRK on the day

What it means for the mRNA platform

Investor conviction in Moderna outside COVID has been fragile for two years, and the market had assigned effectively zero value to the personalized cancer program before Tuesday. A confirmatory Phase 3 win changes the story in three ways:

1. Revenue diversification. A launch trajectory for intismeran — even a slow one — gives Moderna its first credible non-COVID commercial cash-flow stream and reduces reliance on Spikevax revenue, which the company itself has guided lower into 2027.
2. Platform validation. Success in melanoma is a proof point that patient-specific neoantigen encoding actually translates to durable clinical benefit when paired with a checkpoint inhibitor. That de-risks the Phase 3 lung-cancer study Merck initiated last year using the same platform.
3. Optionality on manufacturing. Personalized mRNA vaccines require bespoke, four-to-six-week manufacturing per patient. If demand materializes at commercial scale, Moderna’s existing mRNA plants become a strategic asset that competitors would need years to replicate.

Merck’s angle

For Merck, the readout is directly load-bearing on the biggest strategic question facing the company: what replaces Keytruda’s revenue when its composition-of-matter patents begin cliff-expiring in 2028. Combination regimens that pair Keytruda with a proprietary partner molecule extend the franchise’s competitive moat well past the base drug’s exclusivity. Merck co-financed the mRNA-4157 program in 2022, exercising a $250 million option to participate 50/50 in worldwide costs and profits, so it captures half the economics of any launch.

Risks and what to watch next

• Detailed data. The headline “hit primary endpoint” tells you the p-value cleared 0.05, not the magnitude of benefit. A hazard ratio near 0.55 would be a home run; a hazard ratio near 0.80 would still be positive but far less commercially decisive. Detailed data is expected at a major oncology congress.
• Regulatory timeline. Even with Breakthrough Therapy Designation, an sBLA amendment to Keytruda plus a new BLA for intismeran are separate reviews. First launch is more realistically a 2027 event than a 2026 one.
• Manufacturing scale. Personalized manufacturing at commercial scale has never been done in oncology at the volumes an adjuvant melanoma label would generate. Bottlenecks would compress the launch curve.
• Valuation reset. A ~3x move in a day prices in a substantial share of the good outcome. Selling pressure from event-driven funds that were long the readout could dominate the tape for the next several sessions.

Sources

• Yahoo Finance — MRNA quote page (price, percent change, market cap, after-hours print)
• Yahoo Finance — MRK quote page (price, percent change)
• ClinicalTrials.gov — NCT05933577 (INTerpath-001) (Phase 3 study design, primary endpoint)
• FDA — Breakthrough Therapy Designation (regulatory pathway context)
• Moderna Investor Newsroom (corporate disclosures)
• Merck News (corporate disclosures)

Disclosure: This article is for informational purposes only and is not investment advice.